Development

Hansoh's TYK2 inhibitor HS-10374 meets Phase III endpoints in moderate-to-severe psoriasis

Hansoh's TYK2 inhibitor HS-10374 meets Phase III endpoints in moderate-to-severe psoriasis

Hansoh Pharmaceutical Group (HKEX: 3692) has reported that HS-10374, its oral selective allosteric tyrosine kinase 2 (TYK2) inhibitor, met co-primary endpoints in a pivotal Phase III trial for adults with moderate-to-severe plaque psoriasis. The company said it plans to begin discussions with China's NMPA regarding a new drug application.

In the multicenter, randomized, double-blind, placebo-controlled Phase III study, both the proportion of participants achieving PASI 75 (at least a 75% reduction from baseline in the Psoriasis Area and Severity Index) and the proportion achieving sPGA 0/1 (static Physician's Global Assessment score of 0 or 1 with at least a 2-point improvement from baseline) at week 16 were significantly higher in the HS-10374 group versus placebo. The trial also met multiple secondary endpoints. Hansoh reported that more than half of treated participants achieved PASI 90 and almost one-third achieved PASI 100 at week 16. No numerical data were disclosed; detailed results are expected at an upcoming dermatology conference. The safety profile was described as consistent with other TYK2 inhibitors, with no new safety signals observed.

HS-10374 selectively binds the pseudokinase regulatory domain of TYK2, blocking downstream signaling of interleukin-12 and interleukin-23, cytokines central to psoriasis pathogenesis. Hansoh said it will initiate communications with China's National Medical Products Administration (NMPA) to prepare a new drug application.

The Phase III result follows positive Phase II data presented at CDA 2024, where HS-10374 at 6 mg and 12 mg once daily demonstrated statistically significant PASI 75 and sPGA 0/1 response rates versus placebo in 125 patients over 12 weeks.

The AllSci BriefFree, systematic R&D and deal news. Daily.

Bristol Myers Squibb's Sotyktu (deucravacitinib), an allosteric TYK2 inhibitor approved by the US FDA in September 2022, is the most direct class comparator to HS-10374 and holds a head start both globally and in China. Takeda's zasocitinib, another oral allosteric TYK2 inhibitor that outperformed deucravacitinib in a head-to-head Phase III trial, has an NDA under FDA Priority Review with a decision expected in Q1 2027. Johnson & Johnson's Icotyde (icotrokinra), an oral IL-23 receptor antagonist peptide approved by the FDA in March 2026, adds a third oral mechanism to the competitive field. The undisclosed Phase III numbers will be important in determining how HS-10374 compares with deucravacitinib and zasocitinib on efficacy and safety.

Hansoh's near-term path to market runs through China, where it estimates approximately 5 million patients live with moderate-to-severe psoriasis. The company's autoimmune pipeline also includes HS-20137, an IL-23p19 monoclonal antibody licensed from Quanxin Biotechnology that entered Phase III for psoriasis in 2025, positioning Hansoh with two mechanistically distinct oral and biologic options in the same indication. A Phase II study of HS-10374 in active psoriatic arthritis is also ongoing, which could broaden the asset's addressable population if Phase III data support regulatory filing.


Access the AllSci platform to explore the science behind the news.


Spot something wrong? Report an issue with this article